Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Seguridad y efectividad de la estimulación del área de la rama del paquete izquierda versus la terapia de resincronización cardíaca convencional en la insuficiencia cardíaca (SYNCHRONICITY)

2 de noviembre de 2026 actualizado por: Boston Scientific Corporation

This study will compare two different methods to pace the heart to treat heart failure including:

  1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
  2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

850

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Alabama
      • Huntsville, Alabama, Estados Unidos, 35801
        • Reclutamiento
        • Heart Center Research, LLC
        • Contacto:
          • John Jennings, Dr.
        • Investigador principal:
          • John Jennings, Dr.
      • Mobile, Alabama, Estados Unidos, 36608
        • Reclutamiento
        • Mobile Infirmary Medical Center
        • Contacto:
          • Ernest Matthew Quin, Dr.
        • Investigador principal:
          • Ernest Matthew Quin, Dr.
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85054
        • Reclutamiento
        • Mayo Clinic Phoenix
        • Contacto:
          • Mayank Sardana, MD
        • Investigador principal:
          • Mayank Sardana, MD
    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • Reclutamiento
        • Arrhythmia Research Group
        • Contacto:
          • Devi Nair, Dr.
        • Investigador principal:
          • Devi Nair, Dr.
    • California
      • La Jolla, California, Estados Unidos, 92037
        • Reclutamiento
        • Scripps Memorial Hospital
        • Contacto:
          • Nicolas Olson, MD
        • Investigador principal:
          • Nicolas Olson, MD
      • Los Angeles, California, Estados Unidos, 90048
        • Reclutamiento
        • Cedars Sinai Medical Center
        • Investigador principal:
          • Ashkan Ehdaie, MD
        • Contacto:
          • Ashkan Ehdaie, MD
      • Oakland, California, Estados Unidos, 94609
        • Reclutamiento
        • Alta Bates Summit Medical Center
        • Contacto:
          • Rajan Shah, Dr.
        • Investigador principal:
          • Rajan Shah, Dr.
      • Santa Monica, California, Estados Unidos, 90404
        • Reclutamiento
        • Pacific Heart Institute
        • Contacto:
          • Stephen Tang, MD
        • Investigador principal:
          • Stephan Tang, MD
      • Torrance, California, Estados Unidos, 90505
        • Reclutamiento
        • Torrance Medical Center
        • Investigador principal:
          • Gene Kim, MD
        • Contacto:
          • Gene Kim, MD
      • Ventura, California, Estados Unidos, 93003
        • Reclutamiento
        • Cardiology Associates Medical Group, Inc.
        • Contacto:
          • Jonathan Dukes, Dr.
        • Investigador principal:
          • Jonathan Dukes, Dr.
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Reclutamiento
        • Washington Hospital Center
        • Contacto:
          • Cyrus Hadadi, MD
        • Investigador principal:
          • Cyrus Hadadi, MD
    • Florida
      • Sarasota, Florida, Estados Unidos, 34239
        • Reclutamiento
        • Sarasota Memorial Hospital
        • Contacto:
          • Antonio Moretta, Dr.
        • Investigador principal:
          • Antonio Moretta, Dr.
      • Tampa, Florida, Estados Unidos, 33613
        • Reclutamiento
        • AdventHealth Tampa
        • Investigador principal:
          • Kenneth Yamamura, MD
        • Contacto:
          • Kenneth Yamamura, MD
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30309
        • Reclutamiento
        • Piedmont Hospital
        • Contacto:
          • Kavita Krishnasamy, MD
        • Investigador principal:
          • Kavita Krishnasamy, MD
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University Hospital
        • Contacto:
          • Anand Shah, MD
        • Investigador principal:
          • Anand Shah, MD
    • Idaho
      • Meridian, Idaho, Estados Unidos, 83642
        • Reclutamiento
        • St. Luke's Idaho Cardiology Associates
        • Contacto:
          • Justice Oranefo, MD
        • Investigador principal:
          • Justice Oranefo, MD
    • Illinois
      • Hinsdale, Illinois, Estados Unidos, 60521
        • Reclutamiento
        • University of Chicago
        • Contacto:
          • Shrinath Yeshwant, MD
        • Investigador principal:
          • Shrinath Yeshwant, MD
      • Naperville, Illinois, Estados Unidos, 60540
        • Retirado
        • Midwest Cardiovascular Institute
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46250
        • Reclutamiento
        • Community Heart and Vascular Hospital
        • Contacto:
          • Krishna Malineni, MD
        • Investigador principal:
          • Krishna Malineni, MD
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • Reclutamiento
        • University of Iowa Hospitals and Clinics
        • Investigador principal:
          • Paari Dominic, MD
        • Contacto:
          • Paari Dominic, MD
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40207
        • Reclutamiento
        • Baptist Hospital East Louisville
        • Investigador principal:
          • Kevin Parrott, MD
        • Contacto:
          • Kevin Parrott, MD
    • Massachusetts
      • Fall River, Massachusetts, Estados Unidos, 02720
        • Reclutamiento
        • Southcoast Physicians Group
        • Contacto:
          • Arnoldas Giedrimas, MD
        • Investigador principal:
          • Arnoldas Giedrimas, MD
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Reclutamiento
        • University of Michigan Hospitals
        • Investigador principal:
          • Thomas Crawford, MD
        • Contacto:
          • Thomas Crawford, MD
      • Grand Rapids, Michigan, Estados Unidos, 49525
        • Reclutamiento
        • Corewell Health
        • Contacto:
          • Jawad Wassim, MD
        • Investigador principal:
          • Jawad Wassim, MD
    • Minnesota
      • Duluth, Minnesota, Estados Unidos, 55805
        • Retirado
        • St. Mary's Duluth Clinic Regional Heart Center
      • Saint Cloud, Minnesota, Estados Unidos, 56303
        • Retirado
        • Centracare Heart and Vascular Center
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07932
        • Reclutamiento
        • Morristown Medical Center
        • Contacto:
          • Michael Katz, MD
        • Investigador principal:
          • Michael Katz, MD
    • New York
      • Albany, New York, Estados Unidos, 12211
        • Reclutamiento
        • Capital Cardiology Associates
        • Contacto:
          • Rizwan Alimohammad, MD
        • Investigador principal:
          • Rizwan Alimohammad, MD
      • Flushing, New York, Estados Unidos, 11355
        • Reclutamiento
        • New York Hospital Queens
        • Contacto:
          • Seth Goldbarg, Dr.
        • Investigador principal:
          • Seth Goldbarg, Dr.
      • New York, New York, Estados Unidos, 10021
        • Reclutamiento
        • Weill Cornell Medical University
        • Contacto:
          • Jim Cheung, Dr.
        • Investigador principal:
          • Jim Cheung, Dr.
      • New York, New York, Estados Unidos, 14621
        • Reclutamiento
        • Rochester General Hospital
        • Contacto:
          • Dmitry Chuprun, MD
        • Investigador principal:
          • Dmitry Chuprun, MD
      • Syracuse, New York, Estados Unidos, 13057
        • Reclutamiento
        • SUNY-Upstate Medical University
        • Contacto:
          • Jorge Romero, MD
        • Investigador principal:
          • Jorge Romero, MD
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Reclutamiento
        • Sanger Heart and Vascular Institute
        • Contacto:
          • Navid Nafissi, MD
        • Investigador principal:
          • Navid Nafissi, MD
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke University Medical Center
        • Contacto:
          • Daniel Friedman, MD
        • Investigador principal:
          • Daniel Friedman, MD
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43219
        • Reclutamiento
        • Mount Carmel Health System
        • Contacto:
          • Kamel Addo, MD
        • Investigador principal:
          • Kamel Addo, MD
      • Columbus, Ohio, Estados Unidos, 43214
        • Reclutamiento
        • OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
        • Contacto:
          • Anish Amin, MD
        • Investigador principal:
          • Anish Amin, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Reclutamiento
        • Penn Presbyterian Medical Center
        • Contacto:
          • John Bullinga, MD
        • Investigador principal:
          • John Bullinga, MD
      • Wilkes-Barre, Pennsylvania, Estados Unidos, 18702
        • Reclutamiento
        • Geisinger Wyoming Valley
        • Investigador principal:
          • Pugazhendhi Vijayaraman, MD
        • Contacto:
          • Pugazhendhi Vijayaraman, MD
    • South Dakota
      • Sioux Falls, South Dakota, Estados Unidos, 57108
        • Reclutamiento
        • Avera Heart Hospital of South Dakota
        • Contacto:
          • Christopher Stanton, Dr.
        • Investigador principal:
          • Christopher Stanton, Dr.
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37205
        • Reclutamiento
        • St.Thomas Health
        • Contacto:
          • Ricardo Lugo, MD
        • Investigador principal:
          • Ricardo Lugo, MD
    • Texas
      • Plano, Texas, Estados Unidos, 75093
        • Reclutamiento
        • Heart Hospital Baylor Plano
        • Contacto:
          • Mustafa Dohadwala, MD
        • Investigador principal:
          • Mustafa Dohadwala, MD
      • Tyler, Texas, Estados Unidos, 75701
        • Reclutamiento
        • Christus Trinity Mother Frances Health System
        • Contacto:
          • Stanislov Weiner, Dr.
        • Investigador principal:
          • Stanislov Weiner, Dr.
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Reclutamiento
        • University of Virginia Medical Center
        • Investigador principal:
          • Pamela Mason, MD
        • Contacto:
          • Pamela Mason, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law

  2. Patient meets a guideline-based indication for a de novo CRT-D device

  3. Primary prevention indication for ICD therapy

  4. Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)

  5. NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months

    *GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications

  6. Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment

  7. Patient is willing to participate in LATITUDE™ NXT remote patient monitoring

  8. Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)

  9. Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)

Exclusion Criteria:

  1. Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
  2. Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
  3. Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
  4. Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
  5. Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
  6. Prior or planned mechanical or bioprosthetic tricuspid valve replacement
  7. Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
  8. Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
  9. History of heart transplantation or left ventricular assist device (LVAD) implantation
  10. Less than 1 year of life expectancy at the time of enrollment
  11. Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
  12. History of ventricular septal defect (VSD)
  13. Complex congenital heart disease
  14. Documented diagnosis of cardiac amyloidosis
  15. Known occlusion or other reason limiting central venous access for transvenous leads
  16. Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
  17. Patient currently requiring dialysis
  18. Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
  19. Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
  20. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
  21. Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: CRT Cohort

Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.

Experimental: LBBA Cohort

Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Periodo de tiempo: Through study completion, up to maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to maximum of 5 years
System-related complication-free rate
Periodo de tiempo: 12 months

The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Win ratio composite assessment
Periodo de tiempo: Through study completion, up to a maximum of 5 years

Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life

Through study completion, up to a maximum of 5 years
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Periodo de tiempo: Through study completion, up to a maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to a maximum of 5 years
System-related complication-free rate between randomized arms
Periodo de tiempo: 12 months

System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms.

12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de octubre de 2025

Finalización primaria (Estimado)

1 de noviembre de 2029

Finalización del estudio (Estimado)

1 de noviembre de 2029

Fechas de registro del estudio

Enviado por primera vez

23 de junio de 2025

Primero enviado que cumplió con los criterios de control de calidad

7 de julio de 2025

Publicado por primera vez (Actual)

17 de julio de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • C2403

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .